Siminoff P, Reed F C, Schurig J E
Int Arch Allergy Appl Immunol. 1982;67(2):101-8.
BL-5255 exhibited potent activity in several models of antigen-induced immediate hypersensitivity reactions in rats and guinea pigs. The compound was effective whether administered by oral or parenteral routes and in passively and actively sensitized animals. It appeared to be readily absorbed when given orally. Localized skin and bronchoconstriction reactions in rats were inhibited by the compound by oral doses at 0.014 and 1 mg/kg, respectively. BL-5255 was protective against both IgE- and IgG-mediated reactions in the rat and guinea pig. Its effectiveness versus the systemic anaphylaxis reaction in the guinea pig appears to be due to BL-5255's ability to inhibit both the IgE and IgG1 components of the reaction.
BL - 5255在大鼠和豚鼠的几种抗原诱导的速发型超敏反应模型中表现出强效活性。该化合物无论是通过口服还是肠胃外途径给药，对被动和主动致敏的动物均有效。口服给药时似乎易于吸收。大鼠局部皮肤和支气管收缩反应分别被0.014和1毫克/千克的口服剂量化合物所抑制。BL - 5255对大鼠和豚鼠的IgE和IgG介导的反应均有保护作用。它对豚鼠全身过敏反应的有效性似乎归因于BL - 5255抑制该反应的IgE和IgG1成分的能力。
